Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive vortioxetine for cognitive impairment in early schizophrenia
2021-001333-38Phase 2Active
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vortioxetine in schizophrenia and Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Change in BACS App composite z-score. Started Jul 2021; status: active.
02
Drugs
vortioxetine
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2021-001333-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001333-38.